FGFR3 provides the blueprint for a cell-surface receptor that helps signal when to slow down growth, especially in developing bones and skin. This gene plays an important role in keeping cartilage cells in growth plates from multiplying too much. Certain inherited variants that make the signal too strong can lead to short stature and characteristic bone changes, such as achondroplasia or hypochondroplasia. Other FGFR3 changes can arise only in tumor cells and are seen in some bladder and skin cancers.
What is a gene?
A gene is a stretch of DNA that holds instructions your cells use to make certain molecules or to manage how the body works. In some cases, those instructions are used to produce proteins, which do much of the hands on work inside cells. In other cases, a gene’s main role is to regulate timing, location, and intensity of specific body processes. As a group, genes help guide how your body forms and operates, and they can also affect how you react to food, stress, or medications. More detail on this topic is available in the LearnHub.
Overview
FGFR3Gene function
What if the gene works
FGFR3 helps control how cartilage cells grow, which supports normal bone lengthening during childhood. Its receptor protein responds to growth signals to keep cell growth and division balanced in several tissues, including bone and skin.
Risk
What if the gene does not work
Some changes in the FGFR3 gene make growth signals too strong, causing short stature and limb or spine differences, such as achondroplasia or hypochondroplasia. Depending on the variant, effects can range from mild to severe, and may begin earlier.
Treatment
What does that mean for your treatment
Some FGFR3 gene variants are treated by reducing FGFR3 signaling; vosoritide can help some children with open growth plates. In certain cancers, an FGFR3 alteration can qualify you for FGFR inhibitors, such as erdafitinib.
Conditions associated with FGFR3
Gene function
What if the gene works
Bones lengthen, skin renews itself, and many tissues maintain their shape because cells respond to carefully timed growth signals. In your body, the FGFR3 gene supports processes that let cells “hear” and act on these signals. This is a key part of how the FGFR3 gene helps control bone growth and day-to-day tissue upkeep.
The FGFR3 gene provides instructions for a receptor that sits on the cell surface, like an antenna. When certain natural growth signals attach, the receptor passes the message into the cell so it can respond appropriately.
FGFR3 signaling helps cells balance when to grow, when to slow down, and when to mature into their specialized roles. This supports steady development and helps tissues keep their normal structure over time.
In the growing ends of bones, FGFR3 helps regulate the activity of cartilage cells that shape how bones lengthen. It acts as a natural brake so growth happens at a controlled pace and bones develop with typical proportions.
FGFR3 activity supports normal renewal in tissues such as skin by guiding how cells replace older cells with new ones. This helps maintain an organized layer of cells rather than uneven buildup.
What is a variant?
A genetic variant refers to a minor difference in the DNA sequence within a gene. These differences are widespread and help explain normal variation among people, such as differences in appearance, metabolism, or the way the body reacts to environmental influences. Many variants do not lead to any obvious changes and are part of typical genetic diversity. In certain situations, though, a variant can have a larger effect on how a gene works and may play a role in, or directly cause, a genetic condition.
Genetic variants
What if the gene does not work
Changes in the FGFR3 gene can alter growth signaling in cartilage and bone, which can affect height, limb proportions, and the timing of skeletal changes. Many variants make the signal too active, and the effects can range from milder changes (such as hypochondroplasia) to more severe mutations, including a FGFR3 gene mutation linked to achondroplasia or, in some cases, thanatophoric dysplasia. Less commonly, variants that reduce FGFR3 activity can be associated with taller stature and features like hearing differences.
How variants are linked to conditions
Certain FGFR3 gene mutations can cause inherited conditions that affect bone growth. Pathogenic variants are a well-established cause of achondroplasia and can also lead to hypochondroplasia and the more severe thanatophoric dysplasia; a specific variant can confirm Muenke syndrome (a common craniosynostosis condition). Separately, non-inherited (somatic) FGFR3 variants are frequently found in some bladder cancers and a few other tumors, where they help guide testing and treatment choices.
A variant is not necessarily a diagnosis
Differences in DNA are expected in people and show up frequently across the population. In most situations, these variants do not directly change a person’s health and instead represent normal human variation. For many genes, a variant that has been linked to a condition points to a potential connection rather than a certain diagnosis, particularly when the outcome depends on several genes along with environmental influences. Still, there are situations where one clearly established variant in a particular gene is enough to confirm a diagnosis.
Are there things that can increase or change my risk?
For conditions caused by a harmful change in the FGFR3 gene, the chance of having the condition is mostly set by the gene change, not lifestyle. New FGFR3 changes in a baby are more common when the father is older at conception. After birth, keeping a healthy weight and treating sleep or breathing problems early can lower the risk of complications.
Inheritance of FGFR3 variants
Most health conditions caused by changes in the FGFR3 gene follow an autosomal dominant pattern, meaning a parent with the variant can pass it on to a child of any sex with a 50% chance in each pregnancy. Many people are the first in their family because the variant arose for the first time (de novo). This FGFR3 gene inheritance pattern can affect multiple generations.
What does my FGFR3 result mean for my family?
Seek medical advice if an FGFR3 result raises worries about bone growth or spine problems in you or your child, such as short stature, a larger head, back pain, or frequent ear or hearing issues. A genetics clinician can explain how the result may affect relatives and future pregnancies. They can also guide monitoring and treatment choices, including when imaging or specialist care is helpful.
Genetic information
Genetic testing
How you find out about variants
FGFR3 genetic testing looks for specific changes in DNA using a blood draw or saliva sample. A lab reads the gene’s code, often with targeted testing for a known family variant or broader sequencing, then reports whether a variant was found and how it is classified. Results are interpreted alongside your medical and family history.
When should I consider getting a genetic test?
Consider testing for changes in the FGFR3 gene if you or your child has signs of a condition affecting bone growth, such as very short arms and legs, a larger head, or a curved spine, or if scans in pregnancy suggest these. Testing can also help when there’s a family history of an FGFR3-related condition or early skull bone fusion.
A genetic result is only one part of your health story
Genetic test results can be very informative, yet what they can tell you varies depending on the condition and the specific type of variant found. How your body functions over the years is also shaped by many factors, including lifestyle, environment, age, and your medical history. With some conditions, particularly those affected by many different genes, genetic information offers helpful context but not certainty and makes the most sense when considered together with other parts of care. In other situations, a genetic finding can give a straightforward answer. For topics like how you respond to medications, these results can help you better understand your individual experiences.
Pharmacogenetics
How variants shape your response to medicine
Changes in the FGFR3 gene in some tumors can help predict whether a targeted cancer medicine that blocks FGFR signaling is more likely to work. In this setting, the key information is usually the tumor’s genetic profile rather than an inherited gene change you were born with. More broadly, genetic variation across many genes can influence how your body handles a medication and how sensitive you are to its effects, which is one reason the same drug can work well for one person but cause more side effects or less benefit for another. Genetic information is one piece of the bigger picture that clinicians combine with your diagnosis, other lab results, and your overall health when choosing treatment.
What is Pharmacogenetics?
Pharmacogenetics focuses on how differences in your DNA can affect the way you respond to medicines. It examines relationships between specific genes and specific drugs to explain why the same treatment can have different effects in different people. For many medications, genetic factors can influence how powerfully a drug works or how your body breaks it down. Understanding this can support more informed, more personalized treatment choices. More information on this topic is available in the LearnHub.
Drugs influenced by the FGFR3 gene
When should I seek medical advice?
Seek medical advice if you or your child has short arms or legs, a large head, or other signs of a bone-growth condition linked to the FGFR3 gene. Get urgent care for breathing pauses, worsening snoring, weakness, numbness, or trouble walking, which can mean airway or spine pressure. Share any FGFR3 result with your cancer team; it may affect treatment.
History
The FGFR3 gene became a major focus in the early 1990s as researchers searched for the genetic cause of achondroplasia, the most common form of short-limb short stature. In 1994, studies identified a specific change in the FGFR3 gene (often written as p.Gly380Arg) in most people with achondroplasia, which quickly reshaped diagnosis and family counseling. In recent decades, awareness of this gene’s role has grown. Soon after, other FGFR3 gene variants were linked to related skeletal conditions such as hypochondroplasia and thanatophoric dysplasia, helping clinicians better distinguish similar-looking conditions. As testing became more widely available, families gained clearer answers about recurrence in future pregnancies and the range of possible health needs. More recently, FGFR3-related conditions have also become a key area for developing targeted treatments and structured long-term care guidelines.